Compare ADTN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | OLMA |
|---|---|---|
| Founded | 1985 | 2006 |
| Country | United States | United States |
| Employees | 3338 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 1996 | 2020 |
| Metric | ADTN | OLMA |
|---|---|---|
| Price | $14.98 | $15.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $15.50 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 2.8M | 738.5K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,083,807,000.00 | N/A |
| Revenue This Year | $11.09 | N/A |
| Revenue Next Year | $8.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.46 | N/A |
| 52 Week Low | $7.11 | $3.89 |
| 52 Week High | $18.69 | $36.26 |
| Indicator | ADTN | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 43.64 |
| Support Level | $8.39 | $13.98 |
| Resistance Level | $18.34 | $17.23 |
| Average True Range (ATR) | 0.87 | 0.76 |
| MACD | -0.46 | 0.07 |
| Stochastic Oscillator | 14.62 | 33.98 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.